Approval · Notice of Compliance 9017 · 2007
VIREAD: Notice of Compliance 9017
Issued September 11, 2007
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9017
- Date
- September 11, 2007
- Company
- Gilead Sciences, Inc.Foster City, California, United States
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition to product monograph of drug interaction information with respect to coadministration of tenofovir disoproxil fumarate (tdf) with didanosine (ddl)
- Therapeutic class
- Antiretroviral agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VIREAD | Not yet assigned | — |
Medicinal ingredients
- TENOFOVIR DISOPROXIL FUMARATE 300 MG per TAB